The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects

Pisano, L; Moronesi, Fernando; Falco, Fulvio; Stipa, Elisa; Fabbiani, Nedda; Dolfi, Riccardo; Conoscenti, Enzo; Gloria, Rossana; Pepe, R

doi:10.1016/0049-3848(86)90276-8

Cited by 18 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[35][36][37][38][39][40][41][42][43][44] Several clinical studies indicate the clinical efficacy, safety, and tolerability of sulodexide as an antithrombotic. [45][46][47][48][49][50][51] On the basis of our study, recurrent DVTwhich is common and may also lead to pulmonary embolism -can be effectively controlled or reduced and prevented by sulodexide treatment. 52 In controlled conditions, for established treatments, clinical registries are comparable to clinical trials and can be organized at a reasonable cost.…”

Section: Discussionmentioning

confidence: 99%

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Errichi

Cesarone²,

Belcaro³

et al. 2004

Angiology

View full text Add to dashboard Cite

The aim of this study was to evaluate the prevention of recurrent deep vein thrombosis (R-DVT) with an oral antithrombotic agent (sulodexide) in moderate to high-risk subjects. A group of 405 patients was included into the multicenter registry. Both compression and an exercise program were used as well as a risk-factors control plan. After diagnosis of DVT, patients were treated with oral anticoagulants for 6 months. At the end of this period a coagulation study was made and patients started treatment with oral sulodexide capsules for a period of 24 months. The femoral, popliteal, tibial, and superficial veins were scanned with high-resolution ultrasound at inclusion;scans were repeated at 6, 12, 18, and 24 months. Of the 405 subjects included into the registry 178 in the control group (mean age 52.2; SD 11; M:F=90:88) and 189 in the treatment group (mean age 53.2; SD 10.3; M:F=93:96) completed the analysis period of 24 months. At 6 and 12 months the incidence of R-DVT was lower (p<0.05) in the treatment group. At 24 months the global incidence of R-DVT was 17.9% in the control group and 7.4% in the sulodexide group (p<0.05), 2.42 times lower than in controls. The 2 groups were comparable for age and sex distribution and for the localization of the thrombi at inclusion. Also the 2 groups of dropouts were comparable. In the control group there were 32 recurrent DVTs and 24 subjects lost to follow-up (total of 56) of 202 included subjects (27.7%) in comparison with 28 failures (14 recurrent DVTs and 14 lost subjects) of 203 subjects (13.8%) in the treatment group. This difference was statistically significant. In this analysis the incidence of DVT in controls was 2.07 times higher than in the treatment group subjects. In conclusion sulodexide was effective in reducing recurrent thrombotic events in high-risk subjects.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Errichi

Cesarone²,

Belcaro³

et al. 2004

Angiology

View full text Add to dashboard Cite

show abstract

“…Nineteen out of the 64 studies assessed for eligibility were excluded because they contained no quantitative data that was extractable [106][107][108][109][110][111][112][113][114], did not report any of the chosen endpoints [28,[115][116][117][118][119], their data were not stratified by pathology or treatment [120,121], data were reported without variance [122], or control data were only historical [123].…”

Section: Excluded Studiesmentioning

confidence: 99%

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Introduction: Micro-and macrovascular complications of diabetes are leading morbidities in the world population. They are responsible not only for increased mortality but also severe disabilities, which jeopardize quality of life (e.g., blindness, walking limitations, and renal failure requiring dialysis). The new antidiabetic agents (e.g., glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter inhibitors) are increasingly recognized as breakthrough agents in the treatment of diabetes and prevention of diabetic complications.

show abstract

“…A large number of clinical studies have been performed with sulodexide in this setting, some of which were double-blind,35–39,49,50,69–72 most were placebo-controlled, and some followed an open design 41,73–78. All studies included patients with Leriche-Fontaine stages I–III disease, ranging from no clinical symptoms to intermittent claudication and significant symptoms.…”

Section: Efficacy In Peripheral Vascular Diseasementioning

confidence: 99%

Use of sulodexide in patients with peripheral vascular disease

J¹,

Coronel²,

Aza³

et al. 2010

JBM

View full text Add to dashboard Cite

Sulodexide is a highly purified glycosaminoglycan containing a combination of heparan sulfate with affinity for antithrombin III and dermatan sulfate with affinity for heparin cofactor II. This antithrombotic and antithrombin activity is of great pharmacologic interest and makes sulodexide a suitable drug for the prophylaxis and treatment of arterial and venous peripheral diseases. In arterial pathology, changes in the Winsor Index, improvement in peripheral blood flow, and reduction in pain-free walking distance confirm that treatment with oral sulodexide is effective. Lipid components linked to the genesis of peripheral vascular processes, including triglycerides, total cholesterol, and low-density lipoprotein fractions, as well as plasma and blood viscosity, are reduced by the administration of sulodexide, whereas the high-density lipoprotein fraction increases. Sulodexide inhibits aggregation and adhesion of platelets at the level of the vascular wall, reduces plasma fibrinogen concentrations, reduces plasminogen activator inhibitor-1, and increases tissue plasminogen activator, as well as systemic fibrinolytic and thrombolytic activity, thereby demonstrating efficacy in the treatment of thromboembolic disease. There is no interaction between sulodexide and other drugs used as long-term treatment for peripheral vascular disease. It is well tolerated, and the adverse reactions described after oral administration are related mainly to transient gastrointestinal intolerance, ie, nausea, dyspepsia, and minor bowel symptoms. Sulodexide may become the treatment of choice when dealing with vascular diseases and their complications, as well as for the prevention of venous thromboembolic disease, being particularly indicated in elderly patients, due to its good tolerability and ease of management.

show abstract

The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Controlled study in hyperlipidemic and diabetic subjects

Cited by 18 publications

References 9 publications

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

Use of sulodexide in patients with peripheral vascular disease

Contact Info

Product

Resources

About